Investors

Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Q3 Report 2020

November 5, 2020

Q2 Half Year Report 2020

August 6, 2020

Q1 Report 2020

May 5, 2020

Investor presentations

Investor Presentation Jefferies Virtual London Healthcare Conference November 18, 2020

Results: PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor

Corporate Deck September 2020

Corporate Deck August 2020

Investor Presentation Conference Call 6th July, 2020

Investor Presentation Jefferies Virtual Healthcare Conference June 3rd, 2020

Investor Presentation May 2020

JP Morgan Healthcare Conference, San Francisco, 15th January 2020

1 2 3

Press Releases

ObsEva SA to present at The International Society of Gynecological Endocrinology 19th World Congress – virtual edition, December 2-5, 2020

press release

December 1, 2020

Geneva, Switzerland and Boston, MA – December 1, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…

Read more

ObsEva SA Submits Marketing Authorization Application to the European Medicines Agency for YSELTY® (linzagolix) for the Treatment of Women with Uterine Fibroids

press release

November 24, 2020

  If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options for the management of uterine…

Read more

ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor

press release

November 16, 2020

Over 50% reduction of pre-term delivery within 48hrs of treatment in singleton pregnancy Maternal, fetal and neonatal safety comparable to…

Read more
1 2 3 55

General Meetings

ObsEva Annual General Meeting 2020

June 9, 2020

Read more

ObsEva Annual General Meeting 2019

May 8, 2019

Read more
1 2 3

Upcoming Events

Year End 2020 Financial Results week of 01 March 2021

Event

March 1, 2021


Read more

ObsEva SA hosts live symposium at the SEUD Online Week on Thursday November 5, 2020

Event

December 22, 2020


Read more

ObsEva SA to present at The International Society of Gynecological Endocrinology 19th World Congress – virtual edition, December 2-5, 2020

Event

December 6, 2020


Read more
 

Contacts

ObsEva Switzerland Office

+41 (0)22 552 3840


contact@obseva.ch

ObsEva U.S. Office

+1 857 972 9364


contact@obseva.ch

Media Switzerland & Europe

Shauna Dillon

+41 (0)22 552 1550 Office

+41 79 360 3533 Mobile

shauna.dillon@obseva.ch

Media United States

Shauna Dillon

+41 (0)22 552 1550 Office

+41 (0)79 360 3533 Mobile

shauna.dillon@obseva.ch

Investor relations


.


Shauna Dillon

+41 (0)79 360 3533

ir@obseva.ch

Clinical studies




clinicaltrials@obseva.ch

HR Office

Charlotte Cadoux


charlotte.cadoux@obseva.ch

CEO Office

+41 (0)22 552 1550


shauna.dillon@obseva.ch

 

Sign up for news

 
 

* Type:


InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












Read our privacy policy here.


 

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue